Name change to connect Orphazyme buyer Kempharm with rare disease area

The company that bought embattled biotech company Orphazyme’s main asset in 2022 is now rebranding to align itself closer with its mission to treat rare diseases.
by mikkel aabenhus hemmingsen, translated by daniel pedersen

US-based Kempharm, which in 2022 acquired a Niemann-Pick type C treatment candidate, the main asset of embattled biotech company Orphazyme, is changing names.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading